{"id":"W2951331135","doi":"10.1097/01.hs9.0000562572.63485.4f","title":"PS1070 THE ECHELON‐2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE‐BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T‐CELL LYMPHOMAS","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; CHOP; Internal medicine; Prednisone; Vincristine; Anaplastic large-cell lymphoma; Cyclophosphamide; Oncology; CD30; Lymphoma; Gastroenterology; Surgery; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003034181,0.0003471957,0.00170535,0.00007730116,0.00003059832,0.00001051871,0.00009776137,0.0001010765,0.0001284735],"category_scores_gemma":[0.00004803795,0.0001848839,0.0002157067,0.0002448676,0.0001346408,0.00006676751,0.00004154005,0.00005810393,0.000003358444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002361387,"about_ca_system_score_gemma":0.0001920349,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001840559,"about_ca_topic_score_gemma":0.000511326,"domain_scores_codex":[0.9976652,0.0001804066,0.0009517281,0.0004422269,0.0005104493,0.0002499888],"domain_scores_gemma":[0.9979793,0.0004514345,0.0006456394,0.0006387712,0.0001855123,0.00009937125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8792921,0.0415742,0.07058481,0.0001156142,0.0008112111,0.00002229552,0.003840815,0.00002856765,0.00004518731,0.00001019252,0.00003933077,0.003635724],"study_design_scores_gemma":[0.9409545,0.02528693,0.02636043,0.0001766619,0.00102999,0.000002006971,0.002261846,0.0001035091,0.003534305,0.00000219457,0.0001421146,0.0001454985],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889536,0.001520523,6.911819e-7,0.00009447538,0.0001607187,0.007648424,0.00007423415,0.0000122724,0.00153506],"genre_scores_gemma":[0.9987113,0.0002277382,0.0001350565,0.000008498878,0.00003908662,0.0003285505,0.00008132672,0.00003214181,0.0004363369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06166247,"threshold_uncertainty_score":0.7539346,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02508550920323259,"score_gpt":0.2964247673137847,"score_spread":0.2713392581105521,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}